VK2735: A Literature Course in Six Modules

How this course is organised

This course has six modules and a closing section. Each module explains what the published literature describes, names the studies behind each statement, and ends with an explicit statement of what the evidence cannot support. This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about health, medication or investigational compounds.

One structural point shapes everything below. The verified peer-reviewed papers used for this course concern incretin receptor biology and the clinical study of dual and triple receptor agonists — tirzepatide, retatrutide and the broader obesity pipeline. They do not include a clinical trial publication of VK2735. Where this course discusses doses, endpoints or adverse events, those numbers belong to the cited comparator compounds, not to VK2735, and the distinction is repeated deliberately rather than assumed.

Module 1: What VK2735 is and how it has been studied

VK2735 has been described in the public domain as an investigational peptide agonist acting at two incretin receptors — the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor — developed by Viking Therapeutics and examined in both a subcutaneous formulation and an orally administered formulation. That description places it in a pharmacological class, not in a body of published outcome data: no peer-reviewed trial report of VK2735 appears among the verified papers behind this course.

The class it belongs to

The class itself is well described. Reviewers of incretin physiology explained that GLP-1 and GIP are gut-derived hormones released after nutrient intake that potentiate insulin secretion in a glucose-dependent manner, and that their signalling is altered in type 2 diabetes (PMID 37430117). A separate mechanistic review argued that adding GIP receptor activity to GLP-1 receptor activity could enhance metabolic efficacy beyond GLP-1 alone (PMID 32396843). A pipeline review of obesity pharmacotherapy catalogued single, dual and triple receptor agonists at varying stages of development and noted that many candidates are investigational rather than approved (PMID 38302593).

Limits of the evidence in Module 1

• No verified peer-reviewed clinical trial of VK2735 is cited here; class membership is descriptive, not evidentiary.
• Company descriptions of formulation are not peer-reviewed study data.
• Belonging to a class does not mean a compound shares another compound's measured results.

Module 2: Mechanism as described in the literature

The mechanistic literature on incretin co-agonism is the closest published context for a dual GLP-1/GIP agonist. Researchers reviewing incretin hormones described GLP-1 receptor activation as increasing glucose-dependent insulin secretion, suppressing glucagon at hyperglycaemic levels and slowing gastric emptying, with additional central effects on appetite signalling (PMID 37430117).

GIP's role has been treated as more contested. A dedicated review asked how GIP might enhance GLP-1 therapy and discussed GIP receptor effects on insulin secretion and on adipose tissue, framing combined receptor engagement as a rationale for co-agonist design (PMID 32396843). A review of tirzepatide, a dual GIP/GLP-1 receptor co-agonist, described the pharmacology of engaging both receptors with a single molecule in type 2 diabetes (PMID 36050763).

Mechanistic extension beyond two receptors has also been published. Researchers reported on retatrutide, described as a GIP, GLP-1 and glucagon receptor agonist, in adults with type 2 diabetes (PMID 37385280), and a later review discussed the addition of glucagon receptor agonism as an energy-expenditure-oriented mechanism distinct from incretin signalling alone (PMID 40563436). A broad review of GLP-1 receptor agonists and next-generation incretin-based medications summarised metabolic, cardiovascular and renal mechanisms attributed to the class (PMID 41547366).

Limits of the evidence in Module 2

• Mechanism papers describe receptor pharmacology in general terms; they do not characterise VK2735's receptor potency, selectivity or bias.
• Two molecules acting at the same receptors can differ in half-life, tolerability and tissue exposure.
• Mechanistic plausibility is not an outcome, and no cited review claimed otherwise.

Module 3: Reported outcomes, study by study

This module summarises what the cited studies measured in their own populations. None of these studies administered VK2735.

Limits of the evidence in Module 3

• Every result above belongs to a named comparator compound; none is a VK2735 result, and none should be read as a prediction about VK2735.
• Phase 2 trials such as the retatrutide study were sized for glycaemic and weight endpoints, not for hard outcomes (PMID 37385280).
• Real-world comparative analyses are subject to confounding by indication and channelling, a limitation acknowledged in observational work of this type (PMID 40590655).
• Design and baseline papers report no outcomes at all (PMID 37758044).

Module 4: VK2735 Side Effects: What Studies Report

There is no published adverse-event profile for VK2735 among the verified papers used here. What follows is the adverse-event literature for the incretin co-agonist class, reported as the investigators described it.

Gastrointestinal events

In the phase 2 retatrutide trial in adults with type 2 diabetes, researchers reported that the most common adverse events were gastrointestinal — including nausea, diarrhoea and vomiting — and that these were mostly mild to moderate and occurred more often during dose escalation (PMID 37385280). Reviewers of the tirzepatide programme similarly described gastrointestinal adverse events as the predominant tolerability issue for the dual GIP/GLP-1 co-agonist in type 2 diabetes (PMID 36050763). A broad class review of GLP-1 receptor agonists and next-generation incretin-based medications also summarised gastrointestinal tolerability as a recurring feature of the class (PMID 41547366).

Body-composition changes

A systematic review and network meta-analysis reported that weight reduction with GLP-1 receptor agonists and co-agonists included loss of lean mass as well as fat mass (PMID 39719170). A companion review examined whether resistance exercise could influence that composition of loss during incretin-based pharmacotherapy and treated lean-mass loss as an open clinical question rather than a settled one (PMID 38687506).

Cardiovascular safety signals

A pre-specified meta-analysis of tirzepatide trials reported no increase in major adverse cardiovascular events with tirzepatide relative to comparators (PMID 35210595), and a dedicated cardiovascular outcome trial was designed to test tirzepatide against dulaglutide 1.5 mg in participants with type 2 diabetes and atherosclerotic cardiovascular disease (PMID 37758044).

Limits of the evidence in Module 4

• None of the adverse events above was recorded in a study of VK2735; transferring a tolerability profile between molecules is an assumption, not a finding.
• Trial populations were selected and monitored; event rates in unmonitored settings are unknown.
• Phase 2 trials detect common events, not rare ones (PMID 37385280).
• Reviews summarise adverse events without pooled per-event estimates (PMID 41547366).

Module 5: Pharmacokinetics, where data exist

For VK2735, no pharmacokinetic parameters — half-life, bioavailability, clearance, exposure after oral versus subcutaneous administration — appear in the verified literature cited on this page. That absence is the accurate statement of the evidence.

What the class literature does describe is administration interval as a downstream consequence of molecular engineering. The retatrutide phase 2 trial administered the compound once weekly by subcutaneous injection over 36 weeks, with dose escalation from lower starting doses (PMID 37385280), and reviewers described tirzepatide as a once-weekly subcutaneous agent in the type 2 diabetes programme (PMID 36050763). A pipeline review of future obesity medications discussed the development of both injectable and orally delivered candidates and the formulation challenges specific to peptide absorption (PMID 38302593).

Limits of the evidence in Module 5

• Weekly administration in comparator trials says nothing quantitative about any other molecule's half-life.
• No cited paper reported oral bioavailability figures for a dual GIP/GLP-1 agonist.
• Escalation schedules used in trials were protocol features of those trials only (PMID 37385280).

Module 6: Regulatory status, stated factually

VK2735 is an investigational compound. It is not an approved medicine in the United States, the European Union or other major jurisdictions, and an investigational compound may be studied under regulatory authorisation without being available as a prescription product.

By contrast, the class comparators discussed in this course include marketed products: tirzepatide has been reviewed in the literature as a treatment for type 2 diabetes (PMID 36050763), and dulaglutide 1.5 mg served as an approved active comparator in trials (PMID 37758044). Retatrutide was studied in a phase 2 trial, which is a development stage rather than an approval (PMID 37385280).

Research-use-only material

Peptides supplied as "research use only" (RUO) chemicals are labelled for laboratory work and are not manufactured, tested or released as drug products for human administration. RUO labelling is not an approval pathway and does not signify any regulatory assessment of safety, purity or efficacy.

Compounding

In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally applies to products made from bulk substances that meet defined eligibility criteria — typically components of approved drugs or substances appearing on relevant lists. An investigational compound that has not been approved and is not on those lists does not, on that basis alone, become an eligible compounding ingredient. Regulatory positions and enforcement priorities change over time. This is general regulatory information, not legal advice.

Limits of the evidence in Module 6

• Regulatory status is jurisdiction-specific and time-sensitive; the cited papers address science, not law.
• A compound advancing in development says nothing about eventual approval.
• No cited paper addressed compounding, supply or availability of any compound.

What the studies did not test

Reading the verified literature closely, the following were not examined:

1. VK2735 itself. No cited paper administered VK2735, measured its pharmacokinetics or recorded its adverse events.
2. Head-to-head comparison with VK2735. The comparative studies cited compared tirzepatide, liraglutide, semaglutide, dulaglutide and retatrutide with one another or with placebo (PMID 40590655, PMID 37385280).
3. Long-term outcomes for investigational co-agonists. The retatrutide phase 2 trial ran to 36 weeks and reported metabolic endpoints, not multi-year outcomes (PMID 37385280).
4. Use in healthy people without metabolic disease. The cited trials enrolled participants with type 2 diabetes or related conditions (PMID 37758044).
5. Unsupervised or non-prescription administration. No cited study evaluated any compound outside a monitored research or clinical setting.
6. Combination with other peptides. No cited paper tested stacking or sequencing of incretin agents with other investigational peptides.

The honest summary of this course is narrow: VK2735 has a described class and described formulations, the class it sits in has a substantial and still-growing literature (PMID 41547366), and the specific evidence about this specific molecule is not represented in the peer-reviewed papers cited here. Anyone tracking it would need to follow primary publications as they appear, and any personal health question belongs with a licensed physician.

References

• Incretin hormones and type 2 diabetes (Diabetologia, 2023)
• How May GIP Enhance the Therapeutic Efficacy of GLP-1? (Trends in Endocrinology and Metabolism, 2020)
• Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction (Cardiovascular Diabetology, 2022)
• Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis (Nature Medicine, 2022)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis (Metabolism, 2025)
• Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (Diabetes Care, 2024)
• Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence (Annals of the American Thoracic Society, 2025)
• What is the pipeline for future medications for obesity? (International Journal of Obesity, 2025)
• Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (Lancet, 2026)